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Open access under CC BThe receptor for calcitonin gene-related peptide (CGRP) has been the target for the development of novel
small molecule antagonists for the treatment of migraine. Two such antagonists, BIBN4096BS and MK-
0974, have shown great promise in clinical trials and hence a deeper understanding of the mechanism
of their interaction with the receptor is now required. The structure of the CGRP receptor is unusual since
it is comprised of a hetero-oligomeric complex between the calcitonin receptor-like receptor (CRL) and an
accessory protein (RAMP1). Both the CLR and RAMP1 components have extracellular domains which
interact with each other and together form part of the peptide-binding site. It seems likely that the antag-
onist binding site will also be located on the extracellular domains and indeed Trp-74 of RAMP1 has been
shown to form part of the binding site for BIBN4096BS. However, despite a chimeric study demonstrating
the role of the N-terminal domain of CLR in antagonist binding, no speciﬁc residues have been identiﬁed.
Here we carry out a mutagenic screen of the extreme N-terminal domain of CLR (residues 23–63) and
identify a mutant, Met-42-Ala, which displays 48-fold lower afﬁnity for BIBN4096BS and almost 900-fold
lower afﬁnity for MK-0974. In addition, we conﬁrm that the Trp-74-Lys mutation at human RAMP1
reduces BIBN4096BS afﬁnity by over 300-fold and show for the ﬁrst time a similar effect for MK-0974
afﬁnity. The data suggest that the non-peptide antagonists occupy a binding site close to the interface
of the N-terminal domains of CLR and RAMP1.
 2009 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Calcitonin gene-related peptide (CGRP) is a 37-amino acid
neuropeptide which has been implicated in the pathogenesis of
migraine [1]. There have been concerted efforts within the phar-
maceutical industry to develop novel small molecule antagonists
of the CGRP receptor which have resulted in the development of
two non-peptidic CGRP receptor antagonists (Fig. 1), BIBN4096BS
(Olcegepant [2]) and MK-0974 (Telcagepant [3]). These compounds
have been the subject of clinical trials that conﬁrmed their clinical
efﬁcacy without the cardiovascular side effects commonly associ-
ated with triptans [4,5]. However, despite their clear therapeutic
potential, relatively little is known regarding the molecular mech-
anisms underlying their binding to the CGRP receptor and their
ability to antagonise CGRP action.lly).
Y-NC-ND license.The structure of the CGRP receptor (‘‘CLR/RAMP1”) is unusual
since it is comprised of a hetero-oligomeric complex between an
accessory protein (RAMP1) and the calcitonin receptor-like recep-
tor (CRL), a family B G protein-coupled receptor (GPCR). The CLR
component shares the typical features of all family B GPCRs,
namely an extracellular N-terminal domain of approximately 120
residues and a transmembrane domain consisting of seven trans-
membrane a-helices [6,7]. CLR is retained intracellularly in the
absence of the RAMP partner which it requires for terminal
glycosylation and translocation to the plasma membrane. The
RAMP partner is not only essential for the successful transit of
the CLR component to the cell surface but its particular type also
determines the phenotype of the receptor itself [8]. Hence, while
CRL/RAMP1 complex is a receptor for CGRP, heteromerisation of
CLR with either the other RAMP types (RAMP2 or RAMP3) results
in the formation of adrenomedullin receptors [8]. Interestingly,
other family B GPCRs also interact with RAMPs although in
many cases the effects upon their pharmacology are unexplored
[9]. However, in the case of the calcitonin receptor (CTR), its
Fig. 1. Chemical structures of three CGRP receptor antagonists: BIBN4096BS, MK-0974 and SB-273779.
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the absence of a RAMP to a receptor for amylin in the presence
of a RAMP and, furthermore, the amylin receptor comprising
CTR/RAMP1 also recognises CGRP with high potency [10].
RAMPs have a structure consisting of a single transmembrane
segment and an extracellular domain comprising a three-helical
bundle [11] which is envisaged to interact with the extracellular
domain of CLR to form the peptide-binding site. However, the pau-
city of structural information describing the interaction between
CLR and RAMP1 complicates the task of determining speciﬁc con-
tact points between the receptor and its ligands. Nevertheless, a
speciﬁc interaction between BIBN4096BS and the RAMP1 compo-
nent of CLR/RAMP1 was identiﬁed following the observation that
the antagonist exhibits approximately 200-fold species selectivity
between primate and rat CGRP receptors [2]. The analysis of se-
quence differences between RAMP1 from these species, followed
by associated site-directed mutagenesis studies, revealed that
Trp-74 of human RAMP1 is key to the high-afﬁnity binding of
BIBN4096BS [12]. When mutated to lysine, as found in rat RAMP1,
the antagonist’s afﬁnity was decreased by two orders of magnitude
[12]. MK-0974 also displays a marked species selectivity which is
also RAMP1-dependent, although the speciﬁc residues involved
in mediating this property have not been identiﬁed [3].
Since CLR/RAMP1 and CTR/RAMP1 share similar afﬁnity for
CGRP, yet are selective for BIBN4096BS [10,13] it suggests that
CLR may also contribute directly to the binding of the antagonist.
Indeed, Salvatore et al. [13] exploited this potential difference by
means of a chimeric study of CLR and CTR, demonstrating
that residues 37–63 of the N-terminus of CLR were required for
high-afﬁnity antagonist binding. In order to conﬁrm the direct
role of CLR in antagonist binding and to locate the non-peptide-
binding site more precisely, we carried out a mutagenesis scan of
the ﬁrst 41 residues of the putative mature CLR sequence (residues
23–63).Materials and methods
Constructs. Human CLR with an N-terminal hemagglutinin (HA)
epitope tag (YPYDVPDYA) [8], was provided by Dr. Foord (Glaxo-
SmithKline, Stevenage, UK) and was sub-cloned into pcDNA3(Invitrogen, Renfrew, UK) prior to mutagenesis. Introduction of
the epitope did not effect the pharmacology of the receptor [8].
hRAMP1-pcDNA3.1 was purchased from UMR cDNA (Rolla, MO,
USA).
Site-directed mutagenesis was carried out using the Quik-
Change protocol (Stratagene, La Jolla, CA), following the manufac-
turers instructions. These constructs were used to express the
wild type, and mutant CLR and RAMP1 proteins in COS7 cells.
Cell culture. COS7 cells were cultured in Dulbecco’s Modiﬁed Ea-
gle’s Medium (Sigma, Poole, UK) supplemented with 10% foetal calf
serum (Lonza Wokingham Ltd., Wokingham, UK), 2 mM L-gluta-
mine, 100 U/ml penicillin and 100 lg/ml streptomycin (Invitro-
gen). Cells were transfected with plasmid containing the cDNA
encoding the receptors, using the Lipofectamine 2000 (Invitrogen)
as follows: to two separate 15 ml falcon tubes, 1.6 ml of DMEM
was added. To one tube, a further 30 lg of cDNA and 40 ll of Plus
Reagent (Invitrogen) was introduced. Once 60 ll Lipofectamine
2000 (Invitrogen) had been transferred to the second tube, both
were incubated at room temperature for 15 min. The contents of
the two tubes were then incubated for a further 15 min. During
this time, the COS7 cells were washed twice with phosphate-buf-
fered saline (PBS). The transfection mixture was then added to
the cells and placed back in the 37 C incubator for 4 h. After addi-
tion of 15.5 ml of double serum CM10, the cells were returned to
the incubator for 16 h. The next day, the media, along with trans-
fection complexes were aspirated and replaced with 40 ml of
CM10 and incubated for a further 24 h. The cells were then disso-
ciated using TypLE Express (Invitrogen), centrifuged and resus-
pended in 1 ml Freezing Media (Sigma). After 16 h in a
specialised freezing container at 80 C, the cryovials were placed
in a 140 C freezer for long-term storage.
Ligands. All non-peptide ligands were synthesised and provided
by GlaxoSmithKline. Human a-CGRP (herein referred to as CGRP)
was purchased from Bachem (SaffronWalden, UK). The radioligand
125I-hCGRP was from PerkinElmer Life and Analytical Sciences
(Waltham, MA).
Radioligand binding. Ice-cold distilled water (1.5 ml) was added
to a vial of frozen COS7 cells which was then mixed and centri-
fuged in a bench-top centrifuge for 5 min at 13,000g. The pelleted
cells were resuspended thoroughly in ice-cold distilled water
and centrifuged as previously described. The pellet was then
Table 1
Pharmacological properties of CLR variants co-expressed with wild type RAMP1-WT.
CLR variant CGRP EC50 BIBN4096BS pA2
CLR-WT 9.64 ± 0.06 10.63 ± 0.08
CLR-E23A 9.55 ± 0.04 10.41 ± 0.12
CLR-L24A 9.54 ± 0.07 10.26 ± 0.11
CLR-E25A 9.47 ± 0.10 10.24 ± 0.14
CLR-E26A 9.43 ± 0.13 10.35 ± 0.14
CLR-S27A 9.52 ± 0.10 10.38 ± 0.09
CLR-P28A 9.60 ± 0.08 10.46 ± 0.16
CLR-E29A 9.70 ± 0.07 10.42 ± 0.11
CLR-D30A 9.55 ± 0.09 10.36 ± 0.16
CLR-S31A 9.69 ± 0.09 10.22 ± 0.17
CLR-I32A 9.54 ± 0.08 10.38 ± 0.13
CLR-Q33A 9.16 ± 0.11 10.13 ± 0.13
CLR-L34A 9.55 ± 0.08 10.30 ± 0.11
CLR-G35A 9.47 ± 0.07 10.41 ± 0.11
CLR-V36A 9.69 ± 0.15 10.16 ± 0.13
CLR-T37A 9.34 ± 0.13 10.73 ± 0.06
CLR-R38A 9.48 ± 0.08 10.33 ± 0.13
CLR-N39A 9.59 ± 0.07 10.43 ± 0.17
CLR-K40A 9.44 ± 0.13 10.50 ± 0.13
CLR-M42A 9.49 ± 0.10 8.95 ± 0.09**
CLR-T43A 9.52 ± 0.06 10.05 ± 0.10
CLR-Q45A 9.57 ± 0.12 10.13 ± 0.14
CLR-Y46A 9.54 ± 0.11 10.36 ± 0.15
CLR-E47A 9.49 ± 0.08 10.51 ± 0.14
CLR-Q50A 9.51 ± 0.08 10.19 ± 0.16
CLR-K51A 9.68 ± 0.06 10.47 ± 0.21
CLR-I52A 9.47 ± 0.06 10.28 ± 0.11
CLR-M53A 9.67 ± 0.16 10.31 ± 0.20
CLR-Q54A 9.57 ± 0.14 10.43 ± 0.12
CLR-D55A 9.51 ± 0.11 10.42 ± 0.11
CLR-P56A 9.48 ± 0.10 10.39 ± 0.16
CLR-I57A 9.61 ± 0.16 10.42 ± 0.13
CLR-Q58A 9.69 ± 0.13 10.46 ± 0.15
CLR-Q59A 9.88 ± 0.11 10.07 ± 0.13
CLR-A60L 9.62 ± 0.16 10.46 ± 0.14
CLR-E61A 9.40 ± 0.08 10.45 ± 0.17
CLR-G62A 9.76 ± 0.05 10.58 ± 0.18
CLR-V63A 9.50 ± 0.10 10.64 ± 0.15
** p < 0.01 relative to pA2 of BIBN4096BS at WT receptor.
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10 min prior to centrifugation (13,000g for 30 min). The cells were
then resuspended in ice-cold PBS and centrifuged for 5 min. After
three additional PBS washes, the crude membrane pellet was
resuspended in 1 ml of HEPES binding buffer (HBB; 20 mM HEPES,
100 mM NaCl, 1 mM EDTA, 3 mM MgSO4, pH 7.5) supplemented
with 50 lg/ml bacitracin and forced through a 23G needle.
Aliquots (0.1 ml) were snap-frozen in liquid nitrogen and stored
at 70 C.
Membranes were slowly thawed on ice before diluting to a con-
centration that gave total radioligand binding of <10% total counts
added. In a reaction volume of 200 ll, 75 pM (60,000 cpm) 125I-
hCGRP, various concentrations of unlabelled hCGRP competitor li-
gand (1 lM to 1 pM) and COS7 membranes expressing the receptor
of interest were combined. All ligand and membranes were diluted
to appropriate concentration in HBB supplemented with 0.3% NFM
and 5050 lg/ml bacitracin. Assays were carried out for 1 h in Mul-
tiScreen 96-well Filtration Plates (polyvinylidene ﬂuoride ﬁlters,
0.45 lm pore size, Millipore, Bedford, MA) pre-soaked for 1 h in
1% non-fat milk/PBS. After the incubation, membrane-associated
radioligand was harvested by transferring the assay mixture to
the ﬁltration plate housed in a vacuum manifold. The wells of
the ﬁltration plate were washed three times with 0.2 ml ice-cold
PBS before harvesting the ﬁlter discs. Filter-bound radioactivity
was measured in a gamma counter (RiaStar 5405 counter; Perkin-
Elmer Life and Analytical Sciences, Waltham, MA). Total radioli-
gand bound was <10% and non-speciﬁc binding was 1% of total
counts added.
cAMP assays. COS7 cells transiently expressing the relevant
receptors were thawed at 37 C for 30 min, then washed in PBS
and counted with an automated cell culture analyser (Cedex
AS20, Innovatis). The cells were resuspended in stimulation buffer:
HBSS, 5 mM HEPES, 0.1% BSA, 500 lM IBMX (all Sigma), pH 7.4 at a
concentration of 1  106 cells per ml. Cell number had been opti-
mised from previous experimentation in order that raw data fell
within a range determined by a standard cAMP concentration
curve. Antagonist solutions were prepared in DMSO (Sigma) and
0.1 ll was added to each well of a white 384-well low volume
OptiPlate (Greiner) to give ﬁnal concentrations ranging from
1 lM to 10 pM. Cells (5 ll) were added to each well followed by
15 min incubation at room temperature. At this point 0.1 ll CGRP
at ﬁnal concentrations ranging from 1 lM to 1 pM was added to
each well using a Hummingbird (Digilab Genomic Solutions) fol-
lowed by 5 ll of LANCE Stimulation buffer (PerkinElmer) contain-
ing 0.01 (v/v) Alexa Fluor 647-labelled antibody (resulting in
5000 cells per well and 0.005 (v/v) Alexa Fluor). The plates were
incubated at room temperature for 30 min.
The detection mix was prepared by diluting Eu-W8044 labelled
streptavidin (PerkinElmer) and biotin cAMP (PerkinElmer) in
Detection buffer 2250 and 750-fold, respectively. This mixture
was incubated at room temperature for 30 min to allow complex
formation. Detection mix was (10 ll) added to each well (which
lyses the cells) and incubated for 2 h at room temperature. The
acceptor ﬂuorescence signal was then read at 665 nm on a View-
Lux instrument (PerkinElmer).
Data analysis. Curves in the ﬁgures represent one of at least
three independent experiments for which each point is the mean
of triplicate values with SEM displayed as error bars. All curves
were ﬁtted using non-linear regression with the aid of GraphPad
PRISM 5 software (San Diego, CA). Binding data were normalised
to the maximal speciﬁc binding within each data set and IC50 val-
ues were calculated with a single site binding model. Response
curves were normalised to the maximal binding with CGRP alone.
Antagonist data were analyzed to generate pA2 values [14]. Values
in the tables represent the mean with SEM calculated from at least
three independent experiments.Results and discussion
While it is known that BIBN4096BS interacts with the CGRP
receptor via RAMP1 [12], its high selectivity for the CGRP receptor
(CLR/RAMP1) over the amylin receptor (CTR/RAMP1) implicates
the CLR component in antagonist binding [10,13]. In this study
we have carried out a mutagenesis scan of the ﬁrst 41 residues
of the putative mature CLR sequence (residues 23–63) in order to
identify potential binding sites for non-peptidic antagonists.
Membrane preparations from COS7 cells co-expressing RAMP1-
WT with either CLR-WT or the N-terminal mutations of CLR were
ﬁrst screened for their ability to bind 125I-CGRP in the presence
and absence of 1 lM unlabelled CGRP (data not shown). When
co-expressed with RAMP1-WT, four of the 41 mutant CLR variants
(I41A, A44L, C48A and Y49A) consistently resulted in no detectable
125I-CGRP binding. Since this could indicate either loss of CGRP
afﬁnity, absence of receptor expression or severe indirect struc-
tural disruption of the receptor structure, these mutants were
not analysed further in this study. The remaining 37 mutant CLR
variants resulted in levels of speciﬁc 125I-CGRP binding that were
comparable to CLR-WT, indicating the expression of intact CGRP
receptors and enabling further more detailed pharmacological
analysis.
LANCE cAMP assays were used to carry out concentration re-
sponse curves for CGRP at COS7 cells co-expressing RAMP1-WT
with either CLR-WT or the 37 CLR variants. The mutations had
no signiﬁcant effect upon CGRP potency (Table 1) indicating that
these residues do not play an important role in binding to the pep-
Table 2
Pharmacological properties of wild type CGRP receptor and mutants of RAMP1 and CLR.
Receptor CGRP CGRP BIBN4096BS MK-0974 SB-273779
pIC50 pEC50 pA2 pA2 pA2
CGRP-WT 8.60 ± 0.04 9.64 ± 0.06 10.63 ± 0.08 9.74 ± 0.09 7.10 ± 0.14
CLR-M42A/RAMP1-WT 8.36 ± 0.10 9.49 ± 0.10 8.95 ± 0.09* 6.79 ± 0.06** 7.08 ± 0.14
CLR-WT/RAMP1-W74K 8.33 ± 0.12 9.35 ± 0.15 8.13 ± 0.11* 7.29 ± 0.09* 7.11 ± 0.06
*p < 0.05 and **p < 0.01, relative to same antagonist at WT receptor.
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CGRP-induced receptor activation was analysed using six different
concentrations of the non-peptidic antagonist in order to right-
shift the CGRP concentration response curve and hence determine
pA2 values. Of the 37 mutant receptors, only CLR-M42A resulted in
a signiﬁcant loss of BIBN4096BS afﬁnity (48-fold, p < 0.05), with
pA2 values of 8.95 ± 0.09 at the mutant compared with
10.63 ± 0.08 at CLR-WT (Table 1).
Whole COS7 cells and membrane preparations co-expressing
RAMP1-WT with either CLR-WT or CLR-M42A were analysed in
more detail in order to determine the role of Met-42 (Table 2,
Fig. 2). While the Met-42-Ala mutation had no signiﬁcant effect
upon CGRP afﬁnity or potency, a very substantial reduction in
MK-0974 afﬁnity was observed (891-fold; Fig. 2F).
In addition, the known BIBN4096BS binding residue on RAMP1,
Trp-74, was mutated to Lys, its equivalent in rat [12] and co-ex-
pressed with CLR-WT (Table 2, Fig. 2). As with the co-expression
of CLR-M42A/RAMP1-WT, the CLR-WT/RAMP1-W74K combinationFig. 2. Concentration–response curves for CGRP at the either wild type CGRP recepto
RAMP1-WT” (C,F,I). The effect on the concentration–response curves of various conce
antagonist (blue), 10 pM (red), 100 pM (purple), 1 nM (orange), 10 nM (grey), 100 nM (b
higher for each color. (For interpretation of the references to color in this ﬁgure legend,resulted in normal CGRP afﬁnity and efﬁcacy but displayed re-
duced afﬁnity for both BIBN4096BS (316-fold, Fig. 2B) and MK-
0974 (282-fold, Fig. 2E). Although it was known that MK-0974 dis-
played species selectivity, this is the ﬁrst conﬁrmation that, like
BIBN4096BS, the selectivity is due to the Trp/Lys change at residue
74 of RAMP1.
Hence, both BIBN4096BS and MK-0974 bind to the CGRP recep-
tor in a similar location involving both the RAMP1 (via Trp-74) and
CLR (via Met-42). Interestingly, although the two molecules appear
to share a similar binding site, the interaction with the CLR compo-
nent is more important for MK-0974 than BIBN4096BS. While the
mutation of Trp-74 in RAMP1 resulted in a similar reduction in
afﬁnity for both ligands, MK-0974 was almost 20-fold more sensi-
tive to the Met-42 mutation in CLR.
The afﬁnity of the unrelated non-peptidic antagonist SB-273779
(Fig. 1) was not affected by either the CRL-M42A or RAMP1-W74K
mutations (Fig. 2G–I). SB-273779 has irreversible binding charac-
teristics the CGRP receptor [15] and is non-selective between CGRPr ‘‘CLR-WT/RAMP1-WT” (A,D,G), ‘‘CLR-WT/RAMP1-W74K” (B,E,H) or ‘‘CLR-M42A/
ntrations of the antagonists BIBN4096BS (A–C) and MK-0974 (D–F) is shown: no
lack), 1 lM (green). The concentration range used for SB-273779 (G–I) was 100-fold
the reader is referred to the web version of this paper.)
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differences in structure, it is highly likely that SB-273779 binds
through a different series of amino acids compared with
BIBN4096BS and MK-0974.
The unaltered afﬁnity of both CGRP and SB-273779 demon-
strates that the mutations do not disrupt the structure of the
receptor and suggests that the reduced afﬁnity of BIBN4096BS
and MK-0974 at the mutated receptors results from the disruption
of direct ligand interaction sites mediated by Trp-74 of RAMP1 and
Met-42 of CLR. Furthermore, it suggests that Trp-74 of RAMP1 and
Met-42 of CLR may reside close to the RAMP1/CLR interface. The
crystal structure of the extracellular domain of RAMP1 [11] dem-
onstrates that Trp-74 is solvent exposed and on the outside surface
of the structure. Likewise, analyses of the crystal structures of re-
lated family B GPCR N-terminal domains [16–18] demonstrate that
the equivalent residues to Met-42 of CLR are also on the outside
surface of the domain. Although there are still too many degrees
of freedom to accurately model the CLR–RAMP1 interface, it is
clear that a domain–domain interaction which involves both
residues can be easily accommodated. There is already evidence
within the literature which supports the importance of the
extreme N-terminus of CLR in association of the two constituent
proteins of the CGRP receptor. For example, in a chimeric study
of the parathyroid hormone-1 receptor, it was shown that residues
23–60 from CLR were sufﬁcient for full expression and oligomeri-
sation of RAMP1 with PTH1 receptor.
In principle an antagonist could work by directly intervening in
the conventional association of CLR with RAMP1, thereby disrupt-
ing the peptide-binding site. However, since this complex forms in
the endoplasmic reticulum and is maintained even after endocyto-
sis, it suggests it is highly stable and unlikely to be readily dis-
rupted by an antagonist [19,20]. Nevertheless, a more modest
alteration of the CLR:RAMP1 interface could be envisaged that re-
sults in an allosteric modiﬁcation of the peptide-binding site
(Fig. 3A), with compounds such as BIBN4096BS and MK-0974 act-
ing as a lever between the N-termini of RAMP1 and CLR, breaking
nearby interactions which are critical for binding of the peptidic li-
gand. Indeed, there is evidence that BIBN4096BS acts allosterically
[10] and it is interesting that neither of the mutations that have de-
ﬁned the two known contact sites for these non-peptide antago-
nists disrupt CGRP binding. However, this does not rule out some
degree of overlap at other places in the binding sites and it is pos-
sible that the peptide and non-peptide ligands occupy over-lappingFig. 3. Two models for the mechanism of action of the antagonists BIBN4096BS and
MK-0974. The N-terminal domains of CLR and RAMP1 are depicted by the two
shaded shapes, the antagonist-binding residues Met-42 and Trp-74 are each shown
as small white circles, the antagonist as a black hexagon and the peptide ligand as a
helix. Both A(left) and B(left) depict how the peptide can interact with both
domains but not with the antagonist-binding residues. In A(right) the antagonist
binding at the CLR:RAMP1 interface causes an allosteric effect which alters the
peptide-binding site. In B the antagonist binding (centre) results in the occupation
of some of the space required for the binding of the peptide, leading to competitive
binding (right).space while utilising different residues to obtain high afﬁnity
(Fig. 3B). Hence, it is possible that the non-peptides antagonise
CGRP action by either an indirect allosteric action (Fig. 3A) or by
competing for a partially over-lapping binding site (Fig. 3B).Conclusions
In summary, we have identiﬁed the ﬁrst interaction site on CLR
that interacts with the non-peptide antagonists BIBN4096BS and
MK-0974. In addition, we have shown that the high afﬁnity of
MK-0974, like that of BIBN4096BS, is dependent upon Trp-74 in
RAMP1. The location of these interaction sites highlight the do-
main–domain interface between the extracellular domains of CLR
and RAMP1 and suggest a mechanism to explain the binding and
antagonism of BIBN4096BS and MK-0974.
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